CAS NO: | 1448169-71-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversibleFGFRinhibitor, withIC50s of 3.9, 1.3, 1.6, and 8.3 nM forFGFR1-4, respectively. Futibatinib inhibits mutant and wild-typeFGFR2with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM)[1][2][3]. | ||||||||||||||||
IC50& Target[3] |
| ||||||||||||||||
体外研究 (In Vitro) | Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR[1]. | ||||||||||||||||
体内研究 (In Vivo) | Futibatinib (TAS-120) (3, 30, 100 mg/kg/day, p.o.) exerts an anti-tumor effect in mice. Futibatinib (TAS-120) shows anti-tumor effect by administering at moderate intervals, such as intermittent administration of every other day dosing and 2 times/week, and reducing the sustained elevation and weight suppression blood phosphorus level, and take a antitumor effective as daily administration[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 418.45 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C22H22N6O3 | ||||||||||||||||
CAS 号 | 1448169-71-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 29 mg/mL(69.30 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|